Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance

Vanguard Mega Cap Growth ETFTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Vanguard Mega Cap Growth ETF — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Vanguard Mega Cap Growth ETF trades at $90.18. The key difference: GSK plc pays a 3.57% dividend while Vanguard Mega Cap Growth ETF pays none, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.

GSKMGK
Market Cap
$102.60B
Sector
HealthBroad Market / Factor
52-Week High
$61.18$92.06
52-Week Low
$38.22$70.70
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Vanguard Mega Cap Growth ETF

MGK trades at $90.30, down 0.36% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI readings. The ETF maintains strong institutional interest, with Bay Colony Advisory Group increasing its stake by 378.7% in the latest quarter. Recent news highlights MGK's superior five-year returns compared to small-cap alternatives, though with higher volatility due to its concentrated mega-cap tech focus.

MGK offers exposure to large-cap growth stocks with a low 0.05% expense ratio, delivering strong historical performance but facing concentration risk in technology sectors. The ETF's outlook remains positive given its track record of beating the S&P 500, though investors should monitor tech sector volatility and potential valuation pressures in mega-cap names.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

Read more on MGK